

<b>Effective date: 04/01/2022</b>
Reviewed: 01/2022, 3/2023, 2/2024, 2/2025
Scope: Medicaid

## SPECIALTY GUIDELINE MANAGEMENT

### TAVNEOS (avacopan)

## POLICY

### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met, and the member has no exclusions to the prescribed therapy.

#### FDA-Approved Indication

Adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. Tavneos does not eliminate glucocorticoid use.

All other indications are considered experimental/investigational and not covered benefits.

### II. CRITERIA FOR INITIAL APPROVAL

#### **Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA])**

Authorization of 6 months may be granted for treatment of severe active ANCA-associated vasculitis (GPA and MPA) when all of the following are met:

- A. Documentation that Tavneos will be used in combination with standard therapy (e.g., cyclophosphamide, azathioprine, mycophenolate, rituximab)
- B. Documentation that the member is positive for anti-PR3 or anti-MPO antibody
- C. Documentation that the pre-treatment Birmingham Vasculitis Activity Score (BVAS) version 3 demonstrates the presence of at least one major item, or at least three non-major items, or at least two renal items of hematuria and proteinuria (refer to Appendix)

### III. CONTINUATION OF THERAPY

Authorization of 6 months may be granted for continued treatment for severe active ANCA-associated vasculitis (GPA and MPA) in members with documentation who achieve or maintain positive clinical response as evidenced by stabilization or improvement in the BVAS and the member has not received more than 12 months of therapy with Tavneos.

### IV. QUANTITY LIMIT

- Tavneos 10mg capsules: 6 capsules a day

## V. APPENDIX

## Birmingham Vasculitis Activity Score (version 3)

\*Major items are indicated in bold italics

General <ul style="list-style-type: none"> <li>• Myalgia</li> <li>• Arthralgia/ arthritis</li> <li>• Fever <math>\geq 38^{\circ}\text{C}</math></li> <li>• Weight loss <math>\geq 2\text{ kg}</math></li> </ul>	Cardiovascular <ul style="list-style-type: none"> <li>• Loss of pulses</li> <li>• Valvular heart disease</li> <li>• Pericarditis</li> <li>• Ischemic cardiac pain</li> <li>• Cardiomyopathy</li> <li>• Congestive cardiac failure</li> </ul>
Cutaneous <ul style="list-style-type: none"> <li>• Infarct</li> <li>• Purpura</li> <li>• Ulcer</li> <li>• <b><i>Gangrene</i></b></li> <li>• Other skin vasculitis</li> </ul>	Abdominal <ul style="list-style-type: none"> <li>• Peritonitis</li> <li>• Bloody diarrhea</li> <li>• <b><i>Ischemic abdominal pain</i></b></li> </ul>
Mucous membranes/ eyes <ul style="list-style-type: none"> <li>• Mouth ulcers</li> <li>• Genital ulcers</li> <li>• Adnexal inflammation</li> <li>• Significant proptosis</li> <li>• <b><i>Scleritis/ Episcleritis</i></b></li> <li>• Conjunctivitis/ Blepharitis/ Keratitis</li> <li>• Blurred vision</li> <li>• Sudden vision loss</li> <li>• Uveitis</li> <li>• <b><i>Retinal changes (vasculitis/ thrombosis/ exudate/ hemorrhage)</i></b></li> </ul>	Renal <ul style="list-style-type: none"> <li>• Hypertension</li> <li>• Proteinuria <math>&gt; 1+</math> or <math>&gt; 0.2\text{ g/g creatinine}</math></li> <li>• Hematuria <math>\geq 10\text{ RBCs/hpf}</math></li> <li>• Serum creatinine <math>125\text{-}249\text{ }\mu\text{mol/L}</math> (<math>1.41\text{-}2.82\text{ mg/dL}</math>)</li> <li>• Serum creatinine <math>250\text{-}499\text{ }\mu\text{mol/L}</math> (<math>2.83\text{-}5.64\text{ mg/dL}</math>)</li> <li>• Serum creatinine <math>\geq 500\text{ }\mu\text{mol/L}</math> (<math>5.65\text{ mg/dL}</math>)</li> <li>• <b><i>Rise in serum creatinine <math>&gt; 30\%</math> or fall in creatinine clearance <math>&gt; 25\%</math></i></b></li> </ul>
Ear Nose & Throat <ul style="list-style-type: none"> <li>• Bloody nasal discharge/ crusts/ ulcers/ granulomata</li> <li>• Paranasal sinus involvement</li> <li>• Subglottic stenosis</li> <li>• Conductive hearing loss</li> <li>• <b><i>Sensorineural hearing loss</i></b></li> </ul>	Nervous System <ul style="list-style-type: none"> <li>• Headache</li> <li>• <b><i>Meningitis</i></b></li> <li>• Seizures (not hypertensive)</li> <li>• <b><i>Cerebrovascular accident</i></b></li> <li>• Organic confusion</li> <li>• <b><i>Spinal cord lesion</i></b></li> <li>• <b><i>Cranial nerve palsy</i></b></li> <li>• <b><i>Sensory peripheral neuropathy</i></b></li> <li>• <b><i>Mononeuritis multiplex</i></b></li> </ul>
Chest <ul style="list-style-type: none"> <li>• Wheeze</li> <li>• Nodules or cavities</li> </ul>	Other <ul style="list-style-type: none"> <li>• <b><i>RBC casts and/or glomerulonephritis</i></b></li> </ul>

<b>Effective date: 04/01/2022</b>
Reviewed: 01/2022, 3/2023, 2/2024, 2/2025
Scope: Medicaid

<ul style="list-style-type: none"> <li>• Pleural effusion/ pleurisy</li> <li>• Infiltrate</li> <li>• Endobronchial involvement</li> <li>• <b><i>Massive hemoptysis/ alveolar hemorrhage</i></b></li> <li>• <b><i>Respiratory failure</i></b></li> </ul>	
---	--

## VI. REFERENCES

1. Tavneos [package insert]. Cincinnati, OH: ChemoCentryx, Inc.; December 2024.
2. American College of Rheumatology. 2021 American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis & Rheumatology*. <https://www.vasculitisfoundation.org/wp-content/uploads/2021/07/2021-ACR-VF-Guideline-for-Management-of-ANCA-Associated-Vasculitis.pdf>. Accessed October 21, 2021.
3. Geetha D, Jefferson JA. ANCA-Associated vasculitis: Core curriculum 2020. *Am J Kidney Dis*. 75(1): 124-137.
4. Jayne DRW, Merkel PA, Schall TJ et al. Avacopan for the treatment of ANCA-associated vasculitis [supplemental appendix]. *N Engl J Med*. 2021; 384:599-609. DOI: 10.1056/NEJMoa2023386. [https://www.nejm.org/doi/suppl/10.1056/NEJMoa2023386/suppl\\_file/nejmoa2023386\\_appendix.pdf](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2023386/suppl_file/nejmoa2023386_appendix.pdf). Accessed October 28, 2021.